Skip to content

Safety of Pulsing Heating Device Use on the Skin

Safety of Pulsing Heating Device Use on the Skin

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05427877
Enrollment
25
Registered
2022-06-22
Start date
2022-06-30
Completion date
2023-06-30
Last updated
2022-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Brief summary

We hope to assess the safety of a recurrent heating device for pain relief.

Interventions

DEVICEHeating device (Heatwave Technology)

Heating devices will be applied to the trunk and extremities of the body during the first study visit. During each heating cycle, the temperature will increase quickly from room temperature to a high of 45C and then cycle back down. Each heating cycle is 30 minutes with a 3 minute cool down period where no heat is applied. The maximum temperature used in this study is 45 degrees C (113 degrees F). There will be a total of 3 heating cycles at the visit.

Sponsors

Soovu Labs Inc.
CollaboratorINDUSTRY
Integrative Skin Science and Research
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Individuals in good general health. * No known medical conditions that, in the investigator's opinion, may interfere with study participation. * Subjects 18 year of age and older.

Exclusion criteria

* Individuals who have history of acute or chronic disease that would likely interfere with or increase the risk on study participation at the discretion of the investigator. * Individuals with peripheral neuropathy or a neuropathic condition that would alter their ability to sense pain. * Individuals with clinically significant unstable medical disorders that would disqualify the participant at the discretion of the investigator. * Individuals who have history of a psychological illness or condition that would interfere with their ability to understand and follow the requirements of the study at the discretion of the investigator. * Women who are pregnant.

Design outcomes

Primary

MeasureTime frameDescription
Pain - Visual Analog Scale100 minutesSubjective reporting of pain with 10 point pain scale 0= no pain 10= very severe pain
Erythema (skin redness)100 minutesMeasured with skin colorimeter
Post-inflammatory hyperpigmentation100 minutesMeasured with skin colorimeter

Secondary

MeasureTime frameDescription
Mood and Anxiety Assessment100 minutesSurvey based measure using Likert scale responses
Post-inflammatory hyperpigmentation1 weekMeasured with skin colorimeter
Pain - Visual Analog Scale1 weekSubjective reporting of pain with 10 point pain scale 0= no pain 10= very severe pain
Erythema (skin redness)1 weekMeasured with skin colorimeter

Countries

United States

Contacts

Primary ContactJessica Maloh, ND
jessica@integrativeskinresearch.com9167502463

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026